

Cdo-Targeted Small Molecule Lead Compound Identification for Duchenne Muscular Dystrophy (DMD) Therapy



OTHERS	Lead
Product Type	Small molecule
Indication	Duchenne Muscular Dystrophy (DMD)
Target	CDO (CAM (cell adhesion molecule)-related, downregulated oncogene)
MoA (Mechanism of Action)	Induction of CDO expression in skeletal muscle led to a broad spectrum of regenerative and protective effects. CDO activation alleviated muscle injury responses, reduced fibrotic tissue formation, and enhanced muscle stem cell function, contributing to improved neuromuscular junction (NMJ) stability and overall tissue homeostasis.
Competitiveness	CDO represents a novel and dual-action therapeutic target capable of simultaneously enhancing muscle stem-cell function and NMJ stability in DMD . (A First-in-Class, Orally Active Therapeutic Mechanism for DMD)
Development Stage	Lead
Route of Administration	Oral administration, once daily

Any unauthorized distribution or reproduction of this material is strictly prohibited.